OncoMatch

OncoMatch/Clinical Trials/NCT02582697

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Is NCT02582697 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for germ cell tumor.

Phase 3RecruitingUniversity of SydneyNCT02582697Data as of May 2026

Treatment: Bleomycin (active name: Bleomycin Sulfate) · Etoposide · Cisplatin · Pegylated G-CSF (Pegfilgrastim) · FilgrastimThe purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.

Check if I qualify

Extracted eligibility criteria

Cancer type

Testicular Germ Cell Tumor

Biomarker criteria

Required: AFP overexpression (AFP ≥ 1000ng/mL)

Exceptionally raised tumour markers (AFP ≥ 1000ng/mL and/or HCG ≥ 5000 IU/L) without histologic or cytologic confirmation in the rare case where pattern of metastases consistent with GCT, high tumour burden, and a need to start therapy urgently

Required: CGB overexpression (HCG ≥ 5000 IU/L)

Exceptionally raised tumour markers (AFP ≥ 1000ng/mL and/or HCG ≥ 5000 IU/L) without histologic or cytologic confirmation in the rare case where pattern of metastases consistent with GCT, high tumour burden, and a need to start therapy urgently

Disease stage

Metastatic disease required

Performance status

ECOG 0–3(Limited self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: chemotherapy

Exception: pure seminoma relapsing after adjuvant radiotherapy or adjuvant chemotherapy with 1-2 doses of single agent carboplatin; non-seminoma by IGCCC criteria or stage IV malignant ovarian germ cell tumour with low-dose induction chemotherapy prior to registration due to poor fitness (acceptable regimens: cisplatin 20 mg/m2 days 1-2 and etoposide 100 mg/m2 days 1-2; carboplatin AUC 3 days 1-2 and etoposide 100 mg/m2 days 1-2; or baby-BOP)

Previous chemotherapy or radiotherapy, except if patient has pure seminoma relapsing after adjuvant radiotherapy or adjuvant chemotherapy with 1-2 doses of single agent carboplatin or if patient has non-seminoma by IGCCC criteria or stage IV malignant ovarian germ cell tumour in the rare case where low-dose induction chemotherapy is given prior to registration because patient is not fit enough to receive protocol chemotherapy (eg. organ failure, vena cava obstruction, overwhelming burden of disease). Acceptable regimens include cisplatin 20 mg/m2 days 1-2 and etoposide 100 mg/m2 days 1-2; carboplatin AUC 3 days 1-2 and etoposide 100 mg/m2 days 1-2; or baby-BOP.

Cannot have received: radiotherapy

Exception: pure seminoma relapsing after adjuvant radiotherapy

Previous chemotherapy or radiotherapy, except if patient has pure seminoma relapsing after adjuvant radiotherapy

Lab requirements

Blood counts

ANC ≥1.0 x 10^9/L, Platelet count ≥100 x 10^9/L

Kidney function

estimated creatinine clearance of ≥60 ml/min according to Cockcroft-Gault formula, or GFR formally measured if <60 ml/min or borderline

Liver function

bilirubin ≤1.5 x ULN (≤2.0 x ULN if Gilbert's Syndrome); ALT and AST ≤2.5 x ULN (≤5 x ULN if due to hepatic metastases)

Adequate bone marrow function with ANC ≥1.0 x 10^9/L, Platelet count ≥100 x 10^9/L; Adequate liver function where bilirubin must be ≤1.5 x ULN, except participants with Gilbert's Syndrome where bilirubin must be ≤2.0 x ULN; ALT and AST must be ≤2.5 x ULN, except if the elevations are due to hepatic metastases, in which case ALT and AST must be ≤ 5 x ULN; Adequate renal function with estimated creatinine clearance of ≥60 ml/min according to the Cockcroft-Gault formula, unless calculated to be < 60 ml/min or borderline in which case GFR should be formally measured, eg. with EDTA scan

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Memorial Sloan Kettering Cancer Centre · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify